Objective-To reanalyze data from recent randomized trials of statins to assess whether the benefits and risks of statins are mediated primarily via their LDL-C (low-density lipoprotein cholesterol) lowering effects or via other mechanisms. Approach and Results-We adapted Egger regression, a technique frequently used in Mendelian randomization studies to detect genetic pleiotropy, to reanalyze the available randomized control trial data of statin therapy. For cardiovascular end points, each 1 mmol/L change in LDL-C with statin therapy was associated with a hazard ratio of 0.77 (95% confidence interval, 0.71-0.84) with an intercept that was indistinguishable from zero (intercept, −0.0032; [95% confidence interval, −0.090 to 0.084]; P=0.94), indicating no pleiotropy. For incident diabetes mellitus, a 1 mmol/L change in LDL-C with statin therapy was associated with a hazard ratio of 1.07 (95% confidence interval, 0.99-1.16) and an intercept nondistinguishable from zero (intercept, −0.015; [95% confidence interval, −0.30 to 0.27]; P=0.91), again indicating no pleiotropy. Conclusions-Our reanalysis of the randomized control trial data using Egger regression adds to the existing evidence that the cardiovascular benefits of statins and their association with incident diabetes mellitus are mediated primarily, if not entirely, via their LDL-C lowering properties rather than by any pleiotropic effects. Visual Overview-An online visual overview is available for this article. the goodness of fit of the data when the Egger approach is used (Table 1) and suggesting no directional pleiotropy. For the diabetes mellitus end points, a per mmol/L change in LDL was associated with log-transformed risk ratio of 0.070, which translates into a risk ratio of 1.07 (95% CI, 0.99-1.16; Figure 2 ). Again there was no distinguishable change when the Egger regression technique was used. The intercept using Egger regression was not statistically distinguishable from zero (intercept, −0.015 [95% CI, −0.30 to 0.27], P=0.91). Again, the QR statistic was very close to the null value of 1 and showed no improvement in the goodness of fit when using Egger regression (Table 2 ). This was again consistent with no pleiotropy.
S
tatins directly inhibit HMG-CoA reductase, a critical enzyme regulating de novo intracellular cholesterol synthesis. This leads to upregulation of hepatic LDL (low-density lipoprotein) receptors and lower circulating LDL, which has been presumed to be the primary mechanism producing cardiovascular benefit. Despite prior analyses suggesting that the cardiovascular benefits of statins are mediated mainly by the reduction in LDL-C (LDL cholesterol), 1 there has been ongoing debate as to whether the observed benefits and risks of statins are mediated exclusively via their LDL lowering properties or whether other pleiotropic mechanisms come into play. [2] [3] [4] The findings from the JUPITER trial (Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein) 5 and subsequent meta-analyses, 6, 7 which demonstrated that statins also increase the risk of new-onset diabetes mellitus by yet undetermined mechanisms, as well as the recently completed FOURIER trial (Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease), 8 have reignited this debate. Herein, we present a new approach to address whether the benefits and risks of statins are mediated primarily via their LDL-C lowering effects or via other mechanisms. By adapting Egger regression, a technique frequently used in Mendelian randomization studies to detect genetic pleiotropy, we reanalyze the available randomized trial data of statin therapy.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
We included 25 primary and secondary prevention statin trials that provided information on cardiovascular end points, as well as 12 statin trials that provided data on incident diabetes mellitus. A list of the included trials and the data included in this analysis are available in the online-only Data Supplement. For the cardiovascular end points, the log-transformed hazard ratio for every 1 mmol/L change in LDL was −0.26, which translates into a hazard ratio of 0.77 per mmol/L change in LDL-C (95% confidence interval [CI], 0.71-0.84; Figure 1 ). There was no difference in the slope of the intercept line between the inverse variance weight and Egger regression and the intercept in the Egger regression was not distinguishable from zero (intercept, −0.0032; [95% CI, −0.090 to 0.084]; P=0.94). The Q R statistic ≈1 demonstrating no meaningful improvement to the goodness of fit of the data when the Egger approach is used (Table 1 ) and suggesting no directional pleiotropy.
For the diabetes mellitus end points, a per mmol/L change in LDL was associated with log-transformed risk ratio of 0.070, which translates into a risk ratio of 1.07 (95% CI, 0.99-1.16; Figure 2 ). Again there was no distinguishable change when the Egger regression technique was used. The intercept using Egger regression was not statistically distinguishable from zero (intercept, −0.015 [95% CI, −0.30 to 0.27], P=0.91). Again, the QR statistic was very close to the null value of 1 and showed no improvement in the goodness of fit when using Egger regression (Table 2 ). This was again consistent with no pleiotropy.
Discussion
Our reanalysis of the available randomized control trials (RCTs) suggests that statins do not exert any observable pleiotropic effects in generating their benefit of reducing cardiovascular outcomes or in their risk of incident diabetes mellitus. In fact, the evidence suggests that most, if not all, of their effects are mediated through their LDL lowering mechanism. Our results using standard inverse variance weighting with a fixed intercept, mirror closely the results obtained by Silverman et al 9 in terms of the effects per mmol change in LDL for the reduction in cardiovascular events. It is more difficult to directly compare our results on diabetes mellitus to the analysis by Sattar et al 7 because they reported only a graphical representation of their meta-regression and assessed LDL change as a percent change rather than as an absolute change. Nevertheless, graphically, our results seem similar. In both settings, however, we extend these previous analyses by demonstrating that the intercepts of the Egger regression are not statistically distinguishable from zero, which is consistent with no directional pleiotropy with respect to either of these outcomes. Also, the Q R statistic for both settings is very close to unity, which suggests that the Egger regression provides no meaningful improvement on the goodness of fit for either outcome and is consistent with a lack of pleiotropy.
Although recently used in the context of Mendelian randomization studies, Egger regression can also be applied to the current RCT context. Indeed, Egger regression was initially conceived to evaluate small study bias in meta-analyses of RCTs. 10 In MR (Mendelian randomization)-Egger regression, the intercept indicates whether overall estimates from instruments with a small effect are skewed toward either positive or negative outcomes, because of unbalanced directional pleiotropy. Whereas Mendelian randomization studies are concerned with the effects of the genetic instrumental variable, here we substitute the effect of the genetic instrument with the effect of statins on LDL.
Put another way, if no pleiotropy is present, in studies where the effects of statins on LDL are smaller, the risks and benefits should also be smaller (compared with when larger LDL effects are seen). By extending the MR-Egger approach to the meta-regression context across several statin RCTs, the near zero intercept in our analysis is therefore consistent with the lack of any measurable pleiotropy from statins. If pleiotropy was operational, larger than expected benefits and risks would be observed when LDL change was minimal. Our analysis is therefore in keeping with the notion that the primary effects of statins are mediated nearly entirely via LDL-C. It is important to highlight that our results do not exclude the potential role of downstream secondary effects of directly lowering LDL-C (eg, lower inflammation as a result of directly lowering LDL-C). In our context, directional pleiotropy refers to effects of statins that are independent of their effect of LDL-C. Thus our results do not imply that statins only affect LDL-C. Indeed statins have been shown to have an effect on venous thromboembolic events in JUPITER 11 and may have a role in coagulation. 12 A recent genetic analysis has shown that HMGCR inhibition led not only to a lowering of LDL-C, but also to increased body weight, waist circumference, plasma insulin concentrations, and plasma glucose levels. 13 These results strongly support the notion that several statin effects that may seem pleiotropic, are in fact mediated by their primary on-target effect which is to lower LDL-C by upregulating the LDL receptor, and are therefore, entirely consistent with our findings.
Our results are dependent on the instrument strength independent of direct effect assumption, which assumes that any independent pleiotropic effects are independent of the strength of the effect on LDL-C. To put simply, the instrument strength independent of direct effect assumption holds that a causal effect, in this case between statins and cardiovascular outcomes or incident diabetes mellitus, can still be estimated if pleiotropy is present, as long as the magnitude of the pleiotropy is independent of the statin effect on LDL-C. For example, if one speculated that statins exerted independent pleiotropic effects via their lowering of CRP (C-reactive protein), the instrument strength independent of direct effect assumption would hold true if the change in CRP induced by statins was independent of the change in LDL-C. Although this assumption cannot be directly tested across all possible pleiotropic mechanisms, analyses from the JUPITER trial have shown that changes in LDL-C and CRP are only weakly correlated and that the instrument strength independent of direct effect assumption likely does hold true in this setting. 14 Our results show that statins exert their effects in reducing cardiovascular events and in increasing the risk of diabetes mellitus primarily via a LDL lowering mechanism is in keeping with several lines of evidence. Mendelian randomization studies have shown that, per unit change in LDL, any genetic mechanism of LDL lowering that acts through upregulation of the LDL receptor leads to similar effect sizes on outcomes. 15, 16 In addition, randomized trial evidence demonstrates that lipid lowering agents with different mechanisms of action (eg, statins, ezetimibe, and PCSK9 inhibitors) all lead to similar reductions in cardiovascular outcomes per mmol/L change in LDL-C9. Using Mendelian randomization, similar results have also been predicted recently for incident diabetes mellitus, with similar risks of diabetes mellitus (per unit change in LDL-C) observed across several variants in HMGCR and PCSK9 genes. [16] [17] [18] Although the exact mechanism for statin-related diabetes mellitus has not been elucidated and many theories have been proposed, 19, 20 increased uptake of LDL particles caused by upregulation of pancreatic LDL receptor activity with subsequent tissue injury has been hypothesized, 21, 22 and would be consistent with these findings.
Our analysis has some limitations. First, the Egger regression results are admittedly more robust for the cardiovascular end points than for incident diabetes mellitus risk. This is because of the fact that more trials have available data on cardiovascular end points than new cases of diabetes mellitus. Second, we used data on change in LDL-C because of the availability of this measure in all relevant RCTs. Our analysis focused on excluding pleiotropic effects beyond LDL lowering not differentiating whether these effects are mediated primarily by lowering the cholesterol content or the number of LDL particles. We have shown previously that statin benefit is more strongly correlated to lowering apoB, as opposed to LDL-C, 23 and this has been recently corroborated using Mendelian randomization. 24 Third, it was not possible to estimate the I 2 statistic, which would have allowed us to test the no measurement error assumption because not all studies reported the variance of the LDL change. However, given that sample sizes of each included study was large and the effect of statins on LDL-C is also known to be relatively strong, the no measurement error assumption is likely reasonable in this case. Therefore, based on our results, the evidence is suggestive, if not definitive, that that the benefits of statins on cardiovascular disease reduction and incident diabetes mellitus are mediated primarily, if not entirely by their LDL lowering effect.
Conclusions
Although there remains some debate on statin pleiotropy and off-target effects, a reanalysis of the available RCT data using the technique of Egger regression suggests that the cardiovascular benefits and the risk of diabetes mellitus from statins are not mediated through pleiotropic effects but rather through their primary LDL lowering mechanism of action. 
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